Simiao Yong'an decoction for the treatment of atherosclerosis in animal experiment: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

LIN Yiyi ¹ , ZHAO Chen ² , SHI Zhaofeng ¹ , SONG Ke ¹ , ZHAO Sai ¹ , MA Bin ⁴ , LI Bo ³ , TIAN Guihua ¹ ,  SHANG Hongcai ¹ ,  NIE Bo ¹

1. Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, P.R.China;
2. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P.R.China;
3. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, P.R.China;
4. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P.R.China;

Corresponding?author：

SHANG Hongcai, Email: shanghongcai@foxmail.com; NIE Bo, Email: nieboww_1977@163.com

Keywords：

Simiao Yong'an decoction; Atherosclerosis; Systematic review; Meta-analysis; Experiments on animals

DOI：

10.7507/1672-2531.202012005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the interventional effects of Simiao Yong'an decoction on atherosclerosis animal models.Methods Database including CNKI, WanFang Data, VIP, PubMed, The Cochrane Library, and Web of Science were searched to collect animal experiments on atherosclerosis model intervention by Simiao Yong’an decoction from inception to October 2020. Two reviewers independently screened the literature, extracted data, and used the SYRCLE animal experiment bias risk assessment tool to evaluate risk bias of included studies, and then used RevMan 5.4.1 software for meta-analysis.Results A total of 14 animal experiments were included. The results of meta-analysis showed that compared with the blank model group, the Simiao Yong’an decoction group could reduce the aortic plaque area (SMD=?2.04, 95%CI ?3.35 to ?0.74), the ratio of aortic plaque to lumen area (SMD=?1.72, 95%CI ?2.48 to ?0.97), total cholesterol level (SMD=?0.97, 95 %CI ?1.72 to ?0.22), triglyceride level (SMD=?1.21, 95%CI ?1.82 to ?0.60), low-density lipoprotein cholesterol level (SMD=?1.82, 95%CI ?3.12 to ?1.53), tumor necrosis factor-α level (SMD=?3.36, 95%CI ?4.21 to ?2.52), monocyte chemotactic factor-1 level (SMD=?2.98, 95%CI ?4.60 to ?1.35) and C-reactive protein level (SMD=?0.60, 95%CI ?1.08 to ?0.11); however, in the high-density lipoprotein cholesterol level (SMD=0.66, 95%CI ?0.10 to 1.42) and the level of interleukin 1 (SMD=?1.41, 95%CI ?4.11 to 1.30), the differences were not statistically significant.Conclusions The existing evidence shows that the intervention of Simiao Yong’an decoction in the atherosclerosis model can reduce the aortic plaque area and the ratio of the aortic plaque to the lumen area, reduce total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels, and reduce tumor necrosis factor-α, monocyte chemotactic factor-1, and C-reactive protein levels. Due to limited quality of included studies, more high quality studies are required to verify the above conclusions.

Citation： LIN Yiyi, ZHAO Chen, SHI Zhaofeng, SONG Ke, ZHAO Sai, MA Bin, LI Bo, TIAN Guihua, SHANG Hongcai, NIE Bo. Simiao Yong'an decoction for the treatment of atherosclerosis in animal experiment: a systematic review. Chinese Journal of Evidence-Based Medicine, 2021, 21(5): 559-565. doi: 10.7507/1672-2531.202012005 Copy

1.	安冬青, 吳宗貴. 動脈粥樣硬化中西醫結合診療專家共識. 中國全科醫學, 2017, 20(5): 507-511.
2.	Kuznetsova T, Prange KHM, Glass CK, et al. Transcriptional and epigenetic regulation of macrophages in atherosclerosis. Nat Rev Cardiol, 2020, 17(4): 216-228.
3.	Asztalos BF, Horvath KV, McNamara JR, et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis, 2002, 164(2): 361-369.
4.	尋玉君, 單鵬. 他汀類藥物的不良反應評價. 國際醫藥衛生導報, 2019, 25(16): 2764-2766.
5.	Wang C, Niimi M, Watanabe T, et al. Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries. Atherosclerosis, 2018, 277: 136-144.
6.	黃明艷, 高嘉良, 劉超, 等. 中醫藥辨治動脈粥樣硬化規律探析. 中國臨床保健雜志, 2018, 21(6): 834-837.
7.	Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect, 2013, 121(9): 985-992.
8.	徐冰, 聶波, 徐穎, 等. 基于ApoE-/-小鼠動脈粥樣硬化模型的四妙勇安湯活性部位配伍規律研究. 遼寧中醫雜志, 2013, 40(6): 1250-1252.
9.	吳圣賢, 聶波, 潘美香, 等. 解毒活血法對ApoE-/-小鼠動脈粥樣硬化斑塊PPAR-γ和炎性因子的影響. 遼寧中醫雜志, 2014, 41(5): 1046-1048.
10.	漆仲文, 李萌, 朱科, 等. 四妙勇安湯促進滋養血管成熟化穩定動脈粥樣硬化易損斑塊機制研究. 中華中醫藥雜志, 2019, 34(5): 1998-2001.
11.	張軍平, 李明, 李良軍, 等. 四妙勇安湯調控核因子-κB活性及抑制相關炎癥因子的實驗研究. 中華中醫藥雜志, 2010, 25(3): 372-376.
12.	李萌, 張軍平, 朱科, 等. 四妙勇安湯調控滋養血管網重建穩定ApoE(-/-)小鼠動脈粥樣硬化易損斑塊的實驗研究. 世界科學技術-中醫藥現代化, 2017, 19(12): 1989-1997.
13.	宋珂, 侯彥宏, 蘇都娜, 等. 四妙勇安湯對ApoE(-/-)動脈粥樣硬化小鼠IL-6和MCP-1的影響. 中國現代中藥, 2019, 21(4): 441-447.
14.	金榮. 四妙勇安湯對ApoE(-/-)小鼠動脈粥樣硬化斑塊穩定性的影響及其機制的研究. 北京: 北京中醫藥大學, 2010.
15.	許穎智, 張軍平, 李明, 等. 四妙勇安湯對動脈粥樣硬化斑塊易損指數的影響及機制探討. 中華中醫藥雜志, 2010, 25(12): 2298-2301.
16.	朱宏斌, 郝建軍, 朱旭. 四妙勇安湯對動脈粥樣硬化大鼠SOCS1和SOCS3的影響. 中國醫院藥學雜志, 2013, 33(14): 1122-1125.
17.	朱宏斌, 張耕, 郝建軍. 四妙勇安湯對動脈粥樣硬化大鼠輔助性T細胞相關細胞因子的影響. 醫藥導報, 2013, 32(7): 848-850.
18.	朱宏斌, 郝建軍, 張耕, 等. 四妙勇安湯對動脈粥樣硬化大鼠氧化損傷的保護作用. 中日友好醫院學報, 2013, 27(3): 168-171.
19.	朱宏斌, 郝建軍, 張耕, 等. 四妙勇安湯對動脈粥樣硬化大鼠脂質代謝的影響. 湖北中醫藥大學學報, 2013, 15(3): 17-19.
20.	張軍平, 許穎智, 李明, 等. 四妙勇安湯對動脈粥樣硬化模型兔氧化應激及炎癥反應的影響. 中醫雜志, 2010, 51(1): 72-74.
21.	于紅紅, 唐飛, 喻旭梅, 等. 四妙勇安湯對動脈粥樣硬化模型兔自噬相關因子的影響. 亞太傳統醫藥, 2020, 16(7): 23-25.
22.	漆仲文, 李萌, 朱科, 等. 四妙勇安湯對動脈粥樣硬化小鼠動脈血管斑塊外膜滋養血管通透性的影響. 中國實驗方劑學雜志, 2019, 25(11): 24-28.
23.	張軍平, 彭立, 李明, 等. 四妙勇安湯干預家兔動脈粥樣硬化斑塊形成的實驗研究. 新中醫, 2009, 41(10): 105-107.
24.	劉蓓, 陳立新, 郭鵬, 等. 四妙勇安湯活性部位對ApoE基因敲除小鼠動脈粥樣硬化的藥效學研究. 中西醫結合心腦血管病雜志, 2013, 11(4): 450-451.
25.	彭立, 許穎智, 張光銀, 等. 四妙勇安湯穩定動脈粥樣硬化斑塊的機制研究. 世界科學技術-中醫藥現代化, 2011, 13(2): 287-292.
26.	許穎智, 張軍平, 李明, 等. 四妙勇安湯抑制動脈粥樣硬化易損斑塊炎癥反應機制. 科技導報, 2010, 28(23): 95-98.
27.	張軍平, 彭立, 李明, 等. 四妙勇安湯有效抗炎預防家兔動脈粥樣硬化斑塊形成的研究. 世界中醫藥學會聯合會老年醫學專業委員會成立大會暨第一屆學術會議, 2008.
28.	劉清霞, 張宏穎, 徐利霞, 等. 動脈粥樣硬化斑塊中TNF-α的表達與斑塊穩定性的關系. 中國循證心血管醫學雜志, 2019, 11(04): 441-444.
29.	Jean-Charles PY, Wu JH, Zhang L, et al. USP20 (Ubiquitin-Specific Protease 20) inhibits TNF (Tumor Necrosis Factor)-triggered smooth muscle cell inflammation and attenuates atherosclerosis. Arterioscler Thromb Vasc Biol, 2018, 38(10): 2295-2305.
30.	Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. Curr Pharm Des, 2014, 20(28): 4580-4588.
31.	羅星星, 鄭雪蓮, 張瑞嫻, 等. sd-LDL, LPA和hs-CRP聯合檢測在動脈粥樣硬化診斷中的價值. 國際檢驗醫學雜志, 2019, 40(23): 2897-2899, 2904.
32.	Kaplan M, Shur A, Tendler Y. M1 macrophages but not M2 macrophages are characterized by upregulation of CRP expression via activation of NFκB: a possible role for Ox-LDL in macrophage polarization. Inflammation, 2018, 41(4): 1477-1487.
33.	Latkovskis G, Licis N, Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet, 2004, 31(5): 207-213.
34.	Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol, 2017, 70(18): 2278-2289.

1. 安冬青, 吳宗貴. 動脈粥樣硬化中西醫結合診療專家共識. 中國全科醫學, 2017, 20(5): 507-511.
2. Kuznetsova T, Prange KHM, Glass CK, et al. Transcriptional and epigenetic regulation of macrophages in atherosclerosis. Nat Rev Cardiol, 2020, 17(4): 216-228.
3. Asztalos BF, Horvath KV, McNamara JR, et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis, 2002, 164(2): 361-369.
4. 尋玉君, 單鵬. 他汀類藥物的不良反應評價. 國際醫藥衛生導報, 2019, 25(16): 2764-2766.
5. Wang C, Niimi M, Watanabe T, et al. Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries. Atherosclerosis, 2018, 277: 136-144.
6. 黃明艷, 高嘉良, 劉超, 等. 中醫藥辨治動脈粥樣硬化規律探析. 中國臨床保健雜志, 2018, 21(6): 834-837.
7. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect, 2013, 121(9): 985-992.
8. 徐冰, 聶波, 徐穎, 等. 基于ApoE-/-小鼠動脈粥樣硬化模型的四妙勇安湯活性部位配伍規律研究. 遼寧中醫雜志, 2013, 40(6): 1250-1252.
9. 吳圣賢, 聶波, 潘美香, 等. 解毒活血法對ApoE-/-小鼠動脈粥樣硬化斑塊PPAR-γ和炎性因子的影響. 遼寧中醫雜志, 2014, 41(5): 1046-1048.
10. 漆仲文, 李萌, 朱科, 等. 四妙勇安湯促進滋養血管成熟化穩定動脈粥樣硬化易損斑塊機制研究. 中華中醫藥雜志, 2019, 34(5): 1998-2001.
11. 張軍平, 李明, 李良軍, 等. 四妙勇安湯調控核因子-κB活性及抑制相關炎癥因子的實驗研究. 中華中醫藥雜志, 2010, 25(3): 372-376.
12. 李萌, 張軍平, 朱科, 等. 四妙勇安湯調控滋養血管網重建穩定ApoE(-/-)小鼠動脈粥樣硬化易損斑塊的實驗研究. 世界科學技術-中醫藥現代化, 2017, 19(12): 1989-1997.
13. 宋珂, 侯彥宏, 蘇都娜, 等. 四妙勇安湯對ApoE(-/-)動脈粥樣硬化小鼠IL-6和MCP-1的影響. 中國現代中藥, 2019, 21(4): 441-447.
14. 金榮. 四妙勇安湯對ApoE(-/-)小鼠動脈粥樣硬化斑塊穩定性的影響及其機制的研究. 北京: 北京中醫藥大學, 2010.
15. 許穎智, 張軍平, 李明, 等. 四妙勇安湯對動脈粥樣硬化斑塊易損指數的影響及機制探討. 中華中醫藥雜志, 2010, 25(12): 2298-2301.
16. 朱宏斌, 郝建軍, 朱旭. 四妙勇安湯對動脈粥樣硬化大鼠SOCS1和SOCS3的影響. 中國醫院藥學雜志, 2013, 33(14): 1122-1125.
17. 朱宏斌, 張耕, 郝建軍. 四妙勇安湯對動脈粥樣硬化大鼠輔助性T細胞相關細胞因子的影響. 醫藥導報, 2013, 32(7): 848-850.
18. 朱宏斌, 郝建軍, 張耕, 等. 四妙勇安湯對動脈粥樣硬化大鼠氧化損傷的保護作用. 中日友好醫院學報, 2013, 27(3): 168-171.
19. 朱宏斌, 郝建軍, 張耕, 等. 四妙勇安湯對動脈粥樣硬化大鼠脂質代謝的影響. 湖北中醫藥大學學報, 2013, 15(3): 17-19.
20. 張軍平, 許穎智, 李明, 等. 四妙勇安湯對動脈粥樣硬化模型兔氧化應激及炎癥反應的影響. 中醫雜志, 2010, 51(1): 72-74.
21. 于紅紅, 唐飛, 喻旭梅, 等. 四妙勇安湯對動脈粥樣硬化模型兔自噬相關因子的影響. 亞太傳統醫藥, 2020, 16(7): 23-25.
22. 漆仲文, 李萌, 朱科, 等. 四妙勇安湯對動脈粥樣硬化小鼠動脈血管斑塊外膜滋養血管通透性的影響. 中國實驗方劑學雜志, 2019, 25(11): 24-28.
23. 張軍平, 彭立, 李明, 等. 四妙勇安湯干預家兔動脈粥樣硬化斑塊形成的實驗研究. 新中醫, 2009, 41(10): 105-107.
24. 劉蓓, 陳立新, 郭鵬, 等. 四妙勇安湯活性部位對ApoE基因敲除小鼠動脈粥樣硬化的藥效學研究. 中西醫結合心腦血管病雜志, 2013, 11(4): 450-451.
25. 彭立, 許穎智, 張光銀, 等. 四妙勇安湯穩定動脈粥樣硬化斑塊的機制研究. 世界科學技術-中醫藥現代化, 2011, 13(2): 287-292.
26. 許穎智, 張軍平, 李明, 等. 四妙勇安湯抑制動脈粥樣硬化易損斑塊炎癥反應機制. 科技導報, 2010, 28(23): 95-98.
27. 張軍平, 彭立, 李明, 等. 四妙勇安湯有效抗炎預防家兔動脈粥樣硬化斑塊形成的研究. 世界中醫藥學會聯合會老年醫學專業委員會成立大會暨第一屆學術會議, 2008.
28. 劉清霞, 張宏穎, 徐利霞, 等. 動脈粥樣硬化斑塊中TNF-α的表達與斑塊穩定性的關系. 中國循證心血管醫學雜志, 2019, 11(04): 441-444.
29. Jean-Charles PY, Wu JH, Zhang L, et al. USP20 (Ubiquitin-Specific Protease 20) inhibits TNF (Tumor Necrosis Factor)-triggered smooth muscle cell inflammation and attenuates atherosclerosis. Arterioscler Thromb Vasc Biol, 2018, 38(10): 2295-2305.
30. Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. Curr Pharm Des, 2014, 20(28): 4580-4588.
31. 羅星星, 鄭雪蓮, 張瑞嫻, 等. sd-LDL, LPA和hs-CRP聯合檢測在動脈粥樣硬化診斷中的價值. 國際檢驗醫學雜志, 2019, 40(23): 2897-2899, 2904.
32. Kaplan M, Shur A, Tendler Y. M1 macrophages but not M2 macrophages are characterized by upregulation of CRP expression via activation of NFκB: a possible role for Ox-LDL in macrophage polarization. Inflammation, 2018, 41(4): 1477-1487.
33. Latkovskis G, Licis N, Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet, 2004, 31(5): 207-213.
34. Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol, 2017, 70(18): 2278-2289.

Chinese Journal of Evidence-Based Medicine

Simiao Yong'an decoction for the treatment of atherosclerosis in animal experiment: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content